International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC 2022)
Vienna, Austria 06 August 2022 - 09 August 2022
NADIM II suggests PFS, OS benefits of nivolumab + chemo in resectable NSCLC
Adding nivolumab to paclitaxel-carboplatin chemotherapy in the neoadjuvant setting boosted progression-free survival (PFS) and overall survival (OS) in patients with resectable stage IIIA–B non-small cell lung cancer (NSCLC), according to results of the phase II NADIM II trial from Spain.
NADIM II suggests PFS, OS benefits of nivolumab + chemo in resectable NSCLC
02 Nov 2022
Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?
The first interim analysis of the phase III IMpower010 trial suggests an overall survival (OS) benefit with atezolizumab compared with best supportive care (BSC) in patients with resected non-small cell lung cancer (NSCLC) with PD-L1* tumour cell expression ≥1 percent.
Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?
16 Oct 2022
Pembrolizumab-based regimen continues to show favourable signals for ES-SCLC
In the long-term follow-up of the KEYNOTE-604 study, the combination regimen comprising pembrolizumab and etoposide/platinum (EP*) continued to demonstrate survival benefit as first-line therapy for patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC).
Pembrolizumab-based regimen continues to show favourable signals for ES-SCLC
14 Oct 2022
Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis
In the final progression-free survival (PFS) analysis of the GEMSTONE-301 study, sugemalimab demonstrated sustained efficacy and safety as consolidation treatment for individuals with unresectable stage III non-small cell lung cancer (NSCLC) whose disease had not progressed following either concurrent chemoradiotherapy (cCRT) or sequential CRT (sCRT).